Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 12/20 | 0.59 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.50 |
| ▸ | BMP1 | P13497 | 2/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012919 | 0.94 | APLNR (0.56) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL30200824 | 0.94 | APLNR (0.56) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL25285440 | 0.93 | APLNR (0.52) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL3586758 | 0.85 | APLNR (0.59) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL19285058 | 0.85 | APLNR (0.59) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL27266410 | 0.84 | APLNR (0.58) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL27266465 | 0.84 | APLNR (0.58) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL19812390 | 0.84 | APLNR (0.58) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL16235820 | 0.83 | APLNR (0.65) | APLNRTAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL22894835 | 0.82 | APLNR (0.56) | APLNRTAS2R14BMP1PTGESTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630001-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2024123585-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | SULT1E1, TPMT, SULT1A1 | APLNR 4835/4885TAS2R14 500/4885BMP1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.